Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared Gilles Wandeler, Lloyd Mulenga, Michael J. Vinikoor, Helen Kovari, Manuel Battegay, Alexandra Calmy, Matthias Cavassini, Enos Bernasconi, Patrick Schmid, Carolyn Bolton-Moore, Edford Sinkala, Benjamin H. Chi, Matthias Egger, Andri Rauch International Journal of Infectious Diseases Volume 51, Pages 97-102 (October 2016) DOI: 10.1016/j.ijid.2016.08.028 Copyright © 2016 The Author(s) Terms and Conditions
Figure 1 Proportion of patients with significant fibrosis (A) and cirrhosis (B), by country and HBV status. International Journal of Infectious Diseases 2016 51, 97-102DOI: (10.1016/j.ijid.2016.08.028) Copyright © 2016 The Author(s) Terms and Conditions
Figure 2 Risk factors for significant liver fibrosis (APRI ≥1.5) from multivariable logistic regression, by cohort. International Journal of Infectious Diseases 2016 51, 97-102DOI: (10.1016/j.ijid.2016.08.028) Copyright © 2016 The Author(s) Terms and Conditions
Figure 3 Proportion of patients with significant fibrosis, by country and HBV replication status. International Journal of Infectious Diseases 2016 51, 97-102DOI: (10.1016/j.ijid.2016.08.028) Copyright © 2016 The Author(s) Terms and Conditions